OBJECTIVES: The aim of this study is to evaluate feasibility of salvage 4-week hypofractionated whole breast radiotherapy (WBRT) in patients with in-breast recurrence after receiving intraoperative radiotherapy with electrons (IOERT) for primary breast cancer (BC). METHODS: BC patients who had repeated quadrantectomy underwent modified WBRT with intensity-modulated radiotherapy using Helical Tomotherapy to underdose the IOERT region. This approach, called POLO (Partially Omitted Lobe), excluded the IOERT volume from receiving the full prescription dose. RESULTS: Nine patients were treated with this approach, receiving 45 Gy in 20 fractions. A simultaneous integrated boost of 2.5 Gy in 20 fractions was delivered in 6/9 patients. Dose constraints and planning objectives were reported. No severe toxicity was reported while local control and overall survival were 100%. CONCLUSION: The POLO approach is technically feasible and capable to achieve a significant reduction of radiation dose delivered to the previous treated IOERT area. ADVANCES IN KNOWLEDGE: The study demonstrates the technical and dosimetric feasibility of conservative salvage whole breast radiotherapy, while sparing the area already treated with IORT, in patients with in-breast recurrence.
OBJECTIVES: The aim of this study is to evaluate feasibility of salvage 4-week hypofractionated whole breast radiotherapy (WBRT) in patients with in-breast recurrence after receiving intraoperative radiotherapy with electrons (IOERT) for primary breast cancer (BC). METHODS: BC patients who had repeated quadrantectomy underwent modified WBRT with intensity-modulated radiotherapy using Helical Tomotherapy to underdose the IOERT region. This approach, called POLO (Partially Omitted Lobe), excluded the IOERT volume from receiving the full prescription dose. RESULTS: Nine patients were treated with this approach, receiving 45 Gy in 20 fractions. A simultaneous integrated boost of 2.5 Gy in 20 fractions was delivered in 6/9 patients. Dose constraints and planning objectives were reported. No severe toxicity was reported while local control and overall survival were 100%. CONCLUSION: The POLO approach is technically feasible and capable to achieve a significant reduction of radiation dose delivered to the previous treated IOERT area. ADVANCES IN KNOWLEDGE: The study demonstrates the technical and dosimetric feasibility of conservative salvage whole breast radiotherapy, while sparing the area already treated with IORT, in patients with in-breast recurrence.
Authors: Jayant S Vaidya; Michael Baum; Jeffrey S Tobias; Frederik Wenz; Samuele Massarut; Mohammed Keshtgar; Basil Hilaris; Christobel Saunders; Norman R Williams; Chris Brew-Graves; Tammy Corica; Mario Roncadin; Uta Kraus-Tiefenbacher; Marc Sütterlin; Max Bulsara; David Joseph Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-15 Impact factor: 7.038
Authors: Mohammed R S Keshtgar; Norman R Williams; Max Bulsara; Christobel Saunders; Henrik Flyger; Jaime S Cardoso; Tammy Corica; Neils Bentzon; Nikolaos V Michalopoulos; David J Joseph Journal: Breast Cancer Res Treat Date: 2013-07-23 Impact factor: 4.872
Authors: Gerd Fastner; Christoph Gaisberger; Julia Kaiser; Philipp Scherer; Antonella Ciabattoni; Anna Petoukhova; Elena Sperk; Philip Poortmans; Felipe A Calvo; Felix Sedlmayer; Maria Cristina Leonardi Journal: Radiother Oncol Date: 2020-05-13 Impact factor: 6.280
Authors: Joanne S Haviland; J Roger Owen; John A Dewar; Rajiv K Agrawal; Jane Barrett; Peter J Barrett-Lee; H Jane Dobbs; Penelope Hopwood; Pat A Lawton; Brian J Magee; Judith Mills; Sandra Simmons; Mark A Sydenham; Karen Venables; Judith M Bliss; John R Yarnold Journal: Lancet Oncol Date: 2013-09-19 Impact factor: 41.316
Authors: Grit Welzel; Angela Boch; Elena Sperk; Frank Hofmann; Uta Kraus-Tiefenbacher; Axel Gerhardt; Marc Suetterlin; Frederik Wenz Journal: Radiat Oncol Date: 2013-01-07 Impact factor: 3.481
Authors: Wolfgang Harms; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; D Krug; M D Piroth; M-L Sautter-Bihl; F Sedlmayer; R Souchon; F Wenz; R Sauer Journal: Strahlenther Onkol Date: 2016-03-01 Impact factor: 3.621